Sun, Feb 1, 2015, 7:46 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Mar 8, 2014 1:39 PM Flag

    About 10 months ago (May) Part 2

    continued from Biomedreports (May 2013):

    "Amikacin, Ingredient in Arikace is FDA approved antibiotic for CF. But it wasn't delivered well in lung.Insmed's Liposome technology solves this delivery problem by placing amikacin into a liposome, which allows an extention duration of drug efficacy. Amikacin efficacy suggests that the drug is potentially better than TOBI which brings in annual revenues around $400m.With a market cap near $295M, Insmed appears to be undervalued by at least $100M, if not more.

    As of this morning, Lazard Capital has started its coverage of Insmed with a "buy" rating and a 1 year target of $21 a share." As of late 2013,

    Scott Matusow indicated he was long INSM at that time.

    Lazard has increased their PT to $24 and then to $28.

    Canaccord has increased their PT from $18 to $30 in this time frame.

    Leerink Swann went from $12 to $22 in this time frame.

    Sentiment: Buy

15.46-0.50(-3.13%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Breitburn Energy Partners L.P.
NASDAQFri, Jan 30, 2015 4:00 PM EST
ImmunoGen, Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST